The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of lymphoma (mantle cell, relapsed, refractory) – KTE-X19 (Axicabtagene ciloleucel in the consultation invitation).
We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal.
On receiving updated regulatory timing information from the company developing KTE-X19, NICE has agreed that a consultation on the draft scope and holding a scoping workshop at this time would not be appropriate.
In light of this information, NICE will not be progressing with the scoping exercise at this time. Consequently the consultation on the draft scope will be closed and the scoping workshop arranged for Monday 11 March 2019 at 10:00 will be cancelled.
The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause
If you have any comments or concerns please do not hesitate to contact me as the project manager for this appraisal on (0161 870 3148 or via email on michelle.adhemar@nice.org.uk or scopingta@nice.org.uk)